Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $51.2 million.

  • Avidity Biosciences' Current Deferred Revenue fell 17.33% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 17.33%. This contributed to the annual value of $58.9 million for FY2024, which is 14.89% down from last year.
  • Per Avidity Biosciences' latest filing, its Current Deferred Revenue stood at $51.2 million for Q3 2025, which was down 4.37% from $53.5 million recorded in Q2 2025.
  • Avidity Biosciences' Current Deferred Revenue's 5-year high stood at $69.3 million during Q4 2023, with a 5-year trough of $2.0 million in Q3 2023.
  • Its 3-year average for Current Deferred Revenue is $44.9 million, with a median of $57.4 million in 2025.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first slumped by 63.92% in 2023, then spiked by 3,046.39% in 2024.
  • Over the past 5 years, Avidity Biosciences' Current Deferred Revenue (Quarterly) stood at $4.9 million in 2021, then increased by 26.95% to $6.2 million in 2022, then skyrocketed by 1,021.67% to $69.3 million in 2023, then fell by 14.89% to $58.9 million in 2024, then fell by 17.33% to $51.2 million in 2025.
  • Its Current Deferred Revenue was $51.2 million in Q3 2025, compared to $53.5 million in Q2 2025 and $57.4 million in Q1 2025.